Today: 20 December 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

Creative Media & Community Trust Corporation (NASDAQ: CMCT) said it has signed a definitive agreement to sell its lending division to PG FR Holding, LLC, an affiliate of Atlanta-based Peachtree Group. The deal is expected to generate approximately $31 million
12 November 2025
 ·  ·  ·  ·  · 
Fiserv (FISV, formerly FI) Today: Susquehanna Cuts Price Target to $99; KBW Payments Conference at 12:25 p.m. ET — November 12, 2025

Fiserv (FISV, formerly FI) Today: Susquehanna Cuts Price Target to $99; KBW Payments Conference at 12:25 p.m. ET — November 12, 2025

What happened today Susquehanna trims target to $99, still Positive Susquehanna’s James Friedman reduced his Fiserv target to $99 (from $220), citing adjustments for transitory growth drivers (Argentina inflation effects, Clover-related fee dynamics, license revenue, etc.). Despite the reset, the
12 November 2025
 ·  ·  ·  ·  · 
Opendoor (OPEN) News Today — Nov 12, 2025: CEO Kaz Nejatian Buys $1M in Stock as Warrant Dividend Nears; Shares Hold Gains

Opendoor (OPEN) News Today — Nov 12, 2025: CEO Kaz Nejatian Buys $1M in Stock as Warrant Dividend Nears; Shares Hold Gains

Opendoor Technologies Inc. (NASDAQ: OPEN) is back in the spotlight today after CEO Kaz (Kasra) Nejatian disclosed the open‑market purchase of 125,000 shares—about $1.0 million—ahead of next week’s special warrant dividend. The insider buy, recorded in a Form 4 filed
12 November 2025
 ·  ·  ·  ·  · 
Jumia (JMIA) Q3 2025: Revenue +25%, GMV +21%, Orders Surge; FY‑2025 Loss Guided to $50–55M, Q4’26 Breakeven Target

Jumia (JMIA) Q3 2025: Revenue +25%, GMV +21%, Orders Surge; FY‑2025 Loss Guided to $50–55M, Q4’26 Breakeven Target

Jumia Technologies AG (NYSE: JMIA) reported third‑quarter 2025 results before the U.S. market open today, showing accelerating top‑line growth and improving operating metrics while refining its 2025 loss outlook and reiterating a path to profitability. The Africa‑focused ecommerce group also
12 November 2025
 ·  ·  ·  ·  · 
G4 ‘Severe’ Solar Storm Today (Nov. 12, 2025): X5.1 Flare Triggers Radio Blackouts; Northern Lights Stretch From Mexico to Australia

G4 ‘Severe’ Solar Storm Today (Nov. 12, 2025): X5.1 Flare Triggers Radio Blackouts; Northern Lights Stretch From Mexico to Australia

What’s happening now The U.S. National Oceanic and Atmospheric Administration (NOAA) reports that G4 (Severe) geomagnetic storm levels were reached at 01:20 UTC on Nov. 12 and that G1–G4 conditions could continue overnight, driven by successive coronal mass ejections (CMEs). NOAA
12 November 2025
 ·  ·  ·  · 
Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

What’s new today (Nov. 12) Canaccord bumps target to $107. Before the open, Canaccord Genuity’s Edward Nash inched his VKTX target up by $1 to $107 and kept a Buy rating, framing Viking as a high‑quality obesity asset. The update
12 November 2025
 ·  ·  ·  ·  · 
McCormick (MKC) News Today — Nov 12, 2025: Big Funds Shift Stakes, BofA Adds MKC to ‘Beyond‑AI’ Stock Picks, Shares Edge Higher

McCormick (MKC) News Today — Nov 12, 2025: Big Funds Shift Stakes, BofA Adds MKC to ‘Beyond‑AI’ Stock Picks, Shares Edge Higher

What’s new on November 12, 2025 1) Institutions are repositioning around MKC Two notable fund disclosures hit the tape today: While 13F‑based stories reflect prior‑quarter positions, their publication today adds fresh context to how large holders are sizing MKC into
12 November 2025
 ·  ·  ·  ·  · 
Amaze Holdings (AMZE) Completes The Food Channel Acquisition; Plans Platform Revamp for Culinary Creators — Nov 12, 2025

Amaze Holdings (AMZE) Completes The Food Channel Acquisition; Plans Platform Revamp for Culinary Creators — Nov 12, 2025

NYSE American–listed Amaze Holdings closed its purchase of The Food Channel, paid via a convertible promissory note, and says a refreshed FoodChannel.com will soon serve its 60,000+ food creators. Shares were among early pre‑market movers. Amaze Holdings, Inc.+1 What happened
12 November 2025
 ·  ·  ·  · 
Lucyd (NASDAQ: LUCY) Pops Pre‑Market as Q3 Results Are Expected Today — Rebrand, Exec Moves, and New AI Safety Glasses in Focus (Nov. 12, 2025)

Lucyd (NASDAQ: LUCY) Pops Pre‑Market as Q3 Results Are Expected Today — Rebrand, Exec Moves, and New AI Safety Glasses in Focus (Nov. 12, 2025)

Quick take: Lucyd, Inc. (formerly Innovative Eyewear) is trading sharply higher in Wednesday’s pre‑market ahead of an expected third‑quarter earnings release. Momentum follows an October corporate name change, November executive moves, and last week’s launch of new ANSI‑rated, ChatGPT‑enabled Lucyd
12 November 2025
 ·  ·  ·  ·  · 
FedEx (FDX) Jumps as Profit Outlook Brightens; New SAF at O’Hare & Miami, Japan Transit Gains — What to Know Today (Nov. 12, 2025)

FedEx (FDX) Jumps as Profit Outlook Brightens; New SAF at O’Hare & Miami, Japan Transit Gains — What to Know Today (Nov. 12, 2025)

FDX last trade $267.72, up ~5.4% as of 12:41 UTC (Nov 12). Market move: guidance steadies peak‑season nerves FedEx shares are outperforming today after executives told investors at the Baird Global Industrial Conference that fiscal Q2 adjusted EPS will exceed
12 November 2025
 ·  ·  ·  ·  · 
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about
12 November 2025
 ·  ·  ·  · 
1 … 51 52 53 54 55 … 232
Go toTop